Reimagining Medicine

Company overview Financial review 2023 priorities Appendix FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Group | Full year guidance Core Net Financial Result Expenses expected to be broadly in line vs. 2022 Core Tax Rate Expected to be broadly in line vs. 2022 43 Investor Relations | Q4 2022 Results FINANCIAL PROFILE NOVARTIS | Reimagining Medicine

View entire presentation